(R)-SR-C-107 is an orally active inhibitor developed based on ENL (containing YEAST domain protein), designed to target acute myeloid leukemia (AML). The inhibitor has an IC50 of 40 nM and a KD of 144 nM for ENL. In a xenograft mouse model of AML, (R)-SR-C-107 demonstrated in vivo efficacy, achieving a tumor regression rate of 45% at a dosage of 200 mg/kg (PO, QD).
Molecular Weight:
389.45
Formula:
C21H23N7O
Target:
Epigenetic Reader Domain
* VAT and and shipping costs not included. Errors and price changes excepted
